SMALL LYMPHOCYTIC LYMPHOMA

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for periods of time. About 60 adults with untreated CLL who need therapy will receive the combination. The goal i…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to…

This study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Th…

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination works better than either drug alone to control the cancer. About…

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About …

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a …

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This phase 3 trial compares the experimental drug nemtabrutinib (a daily pill) against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who lack a specific genetic change (TP53 mutation)…

This phase 3 trial tests whether the targeted drug zanubrutinib works better than the standard chemo combination of bendamustine plus rituximab for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 590 participants who cannot tole…

This study tests a combination of four drugs (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV gene). The goal is to see if this combo can achieve…

This phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …

This phase 2 study is testing a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if this triple therapy can improve complete remission rates. The study enrolle…

This phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …

This phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…

This study tests two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if the combination can make cancer undetectable using a sensitive blood test. The treatment length is guided by…

This study tests whether adding a new targeted drug (pirtobrutinib) to a standard two-drug combination (venetoclax and rituximab) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma live longer without their cancer getting worse. About 600 adults who h…

This phase 3 trial compares a new oral targeted drug, pirtobrutinib, against a standard chemo-immunotherapy combination (bendamustine plus rituximab) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 309 participants will be randomly assig…

This early-phase study tests an experimental drug called ABBV-453, given with another cancer drug (obinutuzumab), in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. About 60 participa…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely increase their dose of the drug venetoclax faster than the usual 5-week schedule. About 40 participants with newly diagnosed or returning disease will be grouped…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…